Nanjing Leads Biolabs Reports 8.7-Month Median Survival in EP-NEC Trial
Nanjing Leads Biolabs reported median survival of 8.7 months with LBL-024 in a late-line EP-NEC trial.
Nanjing Leads Biolabs reported median survival of 8.7 months with LBL-024 in a late-line EP-NEC trial.